Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study.

Journal: The Lancet. Oncology
PMID: 38976997

Abstract

BACKGROUND: Current guidelines recommend use of adjuvant imatinib therapy for many patients with gastrointestinal stromal tumours (GISTs); however, its optimal treatment duration is unknown and some patient groups do not benefit from the therapy. We aimed to apply state-of-the-art, interpretable artificial intelligence (ie, predictions or prescription logic that can be easily understood) methods on real-world data to establish which groups of patients with GISTs should receive adjuvant imatinib, its optimal treatment duration, and the benefits conferred by this therapy.

Authors

  • Dimitris Bertsimas
    Dimitris Bertsimas, Jack Dunn, Colin Pawlowski, John Silberholz, Alexander Weinstein, and Ying Daisy Zhuo, Massachusetts Institute of Technology, Cambridge; Eddy Chen, Massachusetts General Hospital Cancer Center; Harvard Medical School; Aymen A. Elfiky, Dana-Farber Cancer Institute; Brigham and Women's Hospital; Harvard Medical School, Boston, MA.
  • Georgios Antonios Margonis
    Operations Research Center, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Suleeporn Sujichantararat
    Operations Research Center, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Angelos Koulouras
    Operations Research Center, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Yu Ma
    Department of Electronic Engineering, Fudan University, Shanghai, China.
  • Cristina R Antonescu
    Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Murray F Brennan
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Javier Martín-Broto
    Medical Oncology Department, Fundación Jimenez Diaz University Hospital, Madrid, Spain; Medical Oncology Department, Hospital General de Villalba, Madrid, Spain; Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz, Madrid, Spain.
  • Seehanah Tang
    Operations Research Center, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Piotr Rutkowski
    Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Martin E Kreis
    Department of General and Visceral Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Katharina Beyer
    Department of General and Visceral Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Jane Wang
    Department of Physical Medicine and Rehabilitation, School of Medicine, University of California, Davis, CA 95616, USA.
  • Elzbieta Bylina
    Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Pawel Sobczuk
    Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Antonio Gutierrez
    Medical Oncology Department, Fundación Jimenez Diaz University Hospital, Madrid, Spain; Medical Oncology Department, Hospital General de Villalba, Madrid, Spain; Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz, Madrid, Spain.
  • Bhumika Jadeja
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • William D Tap
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ping Chi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
  • Samuel Singer
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: singers@mskcc.org.

Keywords

External Resources

Popular Topics
Recent Journals